Financial Performance - Net profit attributable to shareholders for Q1 2024 was CNY 24,952,836.79, representing an 18.11% increase year-over-year[12] - Operating revenue for the first quarter of 2024 was CNY 154,300,499.21, up 5.32% from the same period last year[12] - The total net profit after deducting non-recurring gains and losses was CNY 22,444,690.65, an increase of 17.13% year-over-year[12] - Operating profit for Q1 2024 was ¥25.60 million, up from ¥20.22 million in Q1 2023, reflecting a growth of 26.9%[40] - Net profit for Q1 2024 was ¥24.20 million, compared to ¥20.37 million in Q1 2023, representing an increase of 18.5%[40] - The total profit for Q1 2024 was ¥7,024,423.46, a decrease of 38.5% compared to ¥11,330,297.61 in Q1 2023[42] Assets and Liabilities - Total assets as of March 31, 2024, reached CNY 1,828,859,456.42, an increase of 1.62% compared to the end of 2023[12] - The company’s total liabilities decreased by 41.30% in other current liabilities, primarily due to a reduction in endorsed but unpaid notes[14] - Total liabilities rose to CNY 322,304,925.21 from CNY 317,436,402.86, reflecting an increase of approximately 1.7%[35] - Total assets increased to CNY 1,828,859,456.42 as of March 31, 2024, up from CNY 1,799,788,137.78 at the end of 2023, reflecting a growth of approximately 1.5%[34] - Current assets totaled CNY 936,613,056.69, slightly up from CNY 936,380,215.59, indicating a marginal increase of 0.02%[33] - Non-current assets totaled CNY 892,246,399.73, up from CNY 863,407,922.19, indicating an increase of approximately 3.5%[34] Cash Flow - The net cash flow from operating activities increased by 73.74% to CNY 49,255,130.75, driven by higher cash receipts from sales[14] - In Q1 2024, the company generated a net cash flow from operating activities of CNY 133,184,913.22, an increase from CNY 106,833,810.13 in Q1 2023, representing a growth of approximately 24.5%[45] - Total cash inflow from operating activities was CNY 239,916,793.96, compared to CNY 184,873,697.04 in the same period last year, indicating a year-over-year increase of about 29.8%[45] - The company reported cash outflow from operating activities totaling CNY 106,731,880.74, which is an increase from CNY 78,039,886.91 in Q1 2023, reflecting a rise of approximately 36.8%[45] - Cash flow from investing activities showed a net outflow of CNY 91,759,745.22 in Q1 2024, compared to a net outflow of CNY 106,571,756.76 in Q1 2023, indicating a decrease in cash outflow by about 13.9%[46] Shareholder Information - The total number of shares held by the top ten shareholders increased from 60,771,386 to 63,768,869, representing a 4.9% increase[21] - Beijing Kangruihua holds 34.82% of the shares, with a total of 42,684,326 shares, unchanged from the previous period[21] - The second-largest shareholder, Beijing Shuanglu Pharmaceutical, holds 6.46% with 7,913,036 shares, also unchanged[21] - The company reported no new significant events or changes in shareholder relationships during the reporting period[22] Research and Development - Research and development expenses rose by 48.38% to CNY 17,909,848.02, reflecting increased investment in R&D capabilities[14] - Research and development expenses increased to ¥17.91 million in Q1 2024, up from ¥12.07 million in Q1 2023, marking a rise of 48.5%[39] - Research and development expenses decreased to ¥3,773,681.48 in Q1 2024 from ¥4,687,206.14 in Q1 2023, reflecting a reduction of 19.5%[42] Operational Highlights - The company has plans for market expansion and new product development, focusing on enhancing its competitive edge in the pharmaceutical sector[39] - The gross profit margin for Q1 2024 was approximately 17.5%, compared to 10.0% in Q1 2023, indicating improved profitability[39] - Daily related transactions for the reporting period included purchasing raw materials and services, with an expected amount of CNY 2,000,000 and an actual amount of CNY 60,000[26] - The company has not introduced any new equity incentive plans or employee stock ownership plans during the reporting period[28] Legal and Compliance - There were no pledges or judicial freezes on shares held by shareholders[23] - The company did not engage in any significant litigation, arbitration, or external guarantees during the reporting period[25] - The company has fulfilled previously disclosed commitments without any new commitments during the reporting period[29]
星昊医药(430017) - 2024 Q1 - 季度财报